Claritev (NYSE:CTEV - Get Free Report) CEO Travis Dalton purchased 15,380 shares of the stock in a transaction dated Friday, February 27th. The shares were acquired at an average price of $13.00 per share, with a total value of $199,940.00. Following the transaction, the chief executive officer owned 24,952 shares in the company, valued at $324,376. This trade represents a 160.68% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Claritev Price Performance
Shares of NYSE CTEV opened at $14.42 on Tuesday. The company's 50 day simple moving average is $28.38 and its 200 day simple moving average is $46.29. Claritev has a fifty-two week low of $12.04 and a fifty-two week high of $74.07. The firm has a market capitalization of $238.06 million, a P/E ratio of -0.83 and a beta of 0.50.
Analyst Upgrades and Downgrades
Several research analysts have recently issued reports on CTEV shares. Weiss Ratings restated a "sell (d-)" rating on shares of Claritev in a research report on Monday, December 29th. Wells Fargo & Company set a $30.00 price objective on Claritev and gave the company an "equal weight" rating in a report on Tuesday, February 24th. Guggenheim restated a "buy" rating on shares of Claritev in a report on Tuesday, February 24th. Citigroup decreased their target price on Claritev from $63.00 to $21.00 and set a "buy" rating for the company in a research report on Wednesday, February 25th. Finally, UBS Group reaffirmed a "buy" rating on shares of Claritev in a research note on Tuesday, February 24th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Claritev has an average rating of "Hold" and an average target price of $29.67.
Check Out Our Latest Report on CTEV
Hedge Funds Weigh In On Claritev
Several institutional investors and hedge funds have recently modified their holdings of the business. Invesco Ltd. raised its holdings in Claritev by 4.8% during the 4th quarter. Invesco Ltd. now owns 22,802 shares of the company's stock worth $975,000 after buying an additional 1,044 shares during the period. FAS Wealth Partners Inc. boosted its holdings in shares of Claritev by 20.5% in the fourth quarter. FAS Wealth Partners Inc. now owns 31,097 shares of the company's stock valued at $1,329,000 after buying an additional 5,290 shares during the period. XTX Topco Ltd bought a new stake in shares of Claritev during the fourth quarter worth $729,000. Arini Captial Management Ltd acquired a new stake in shares of Claritev during the fourth quarter worth $64,291,000. Finally, Third Point LLC bought a new stake in Claritev in the 4th quarter valued at $6,199,000. 87.15% of the stock is currently owned by institutional investors and hedge funds.
About Claritev
(
Get Free Report)
Claritev is a healthcare technology, data and insights company focused on improving affordability, transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
